Journal Article (Review Article)

DKFZ-2025-00989

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.

Cicala, C. M. ; Bauer, S.DKFZ* ; Heinrich, M. C. ; Serrano, C.

2025
Elsevier Amsterdam [u.a.]

This record in other databases:  

Please use a persistent id in citations: doi:10.1016/j.hoc.2025.04.006

Abstract: This review discusses the current and future landscape of advanced gastrointestinal stromal tumor (GIST) treatment. It covers the role of tyrosine kinase inhibitors (TKIs), specifically imatinib, and further treatment options, such as sunitinib, regorafenib, and ripretinib, as well as avapritinib for platelet-derived growth factor receptor alpha D842V mutations. In addition, this review emphasizes individualized treatment strategies within multidisciplinary expert teams, including surgery and other locoregional therapies, together with the importance of mutation-guided approaches, particularly for wild-type GISTs. Finally, it explores the potential of next-generation KIT inhibitors, combination therapies, and other investigational approaches.

Keyword(s): Gastrointestinal stromal tumor (GIST) ; Imatinib ; KIT mutation ; PDGFRA mutation ; Targeted therapy ; Tyrosine-kinase inhibitors (TKIs)

Note: Volume 39, Issue 4, August 2025, Pages 773-784

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Essen/Düsseldorf (ED01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2025

---

Database coverage:
; BIOSIS Previews ; BIOSIS Reviews Reports And Meetings ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Essential Science Indicators ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---